Virtus LifeSci Biotech Clinical Trials ETF Rating $42.71 0.00 (0.00%) As of 05/22/2026 04:10 PM Eastern Add Compare Share Share Ratings Stock AnalysisChartDividendHoldingsRatingsShort InterestBuy This Stock Virtus LifeSci Biotech Clinical Trials ETF Aggregate Rating and Price Target (2026)How MarketBeat Aggregates ETF Rating and Price TargetMarketBeat calculates the aggregate rating and price target for an ETF by considering the weight of each stock in its portfolio. These ratings and price targets are based on the most recent ratings given by Wall Street analysts over the past year. The aggregate rating reviews the ETF's overall performance and is categorized as strong sell, sell, reduce, hold, moderate buy, buy, or strong buy. The aggegreate price target represents the average potential upside for the consensus price target of individual holdings in the ETF.BBC Aggregate RatingModerate Buy 2.74Holdings in BBC have an aggregate rating of Moderate Buy based on 306 analyst ratings issued in the past year covering 25 companies (34.3% of the portfolio).BBC Aggregate Price Target$42.71High Prediction$42.71Average Prediction$42.71Low Prediction$42.71Holdings in BBC have an aggregate price target of $42.71 and a range of $42.71 to $42.71 covering 25 companies (34.3% of the portfolio).BBC Consensus Ratings of HoldingsStrong Buy0 Strong Buy rating(s)Buy5 Buy rating(s)Moderate Buy16 Moderate Buy rating(s)Hold4 Hold rating(s)Reduce0 Reduce rating(s)Sell0 Sell rating(s)Strong Sell0 Strong Sell rating(s) Ratings for Stocks Held by Virtus LifeSci Biotech Clinical Trials ETF Strong Sell Sell Reduce Hold Moderate Buy Buy Strong Buy Ratings for the Top 25 BBC Holdings ExportWeight In ETFCompanyShare PriceMarketRank™Consensus Rating ScoreConsensus Price TargetPossible UpsideNumber of RatingsIndicator(s)ViewRatings2.13%ERASErasca$11.243.2177 of 5 stars2.50$18.75 66.8%102.00%TNGXTango Therapeutics$20.242.4403 of 5 stars2.64$32.27 59.5%14Gap Up1.89%ELVNEnliven Therapeutics$41.542.8402 of 5 stars2.83$58.40 40.6%6Gap Up1.66%SYRESpyre Therapeutics$74.052.5833 of 5 stars3.00$90.25 21.9%131.59%ALMSAlumis$22.023.7586 of 5 stars2.83$40.30 83.0%121.53%ORKAOruka Therapeutics$60.613.635 of 5 stars2.82$120.80 99.3%11Gap Down1.49%DNTHDianthus Therapeutics$86.482.2287 of 5 stars3.00$117.82 36.2%14Gap Up1.39%CRVSCorvus Pharmaceuticals$12.612.3546 of 5 stars2.71$33.33 164.3%71.39%RVMDRevolution Medicines$151.562.6358 of 5 stars3.00$111.35 -26.5%21Positive News1.36%RZLTRezolute$3.252.1402 of 5 stars2.45$8.75 169.2%11Gap Up1.32%CGONCG Oncology$64.252.7552 of 5 stars2.71$81.73 27.2%141.29%DFTXDefinium Therapeutics$22.502.9572 of 5 stars3.00$37.92 68.5%151.26%LQDALiquidia$60.983.2474 of 5 stars2.92$49.33 -19.1%121.23%GHRSGH Research$22.122.9034 of 5 stars2.73$40.38 82.5%11Gap Up1.23%JBIOJade Biosciences$22.212.0982 of 5 stars2.89$34.33 54.6%9Gap Up1.22%KODKodiak Sciences$36.231.4948 of 5 stars2.63$42.14 16.3%81.21%RLAYRelay Therapeutics$13.532.9469 of 5 stars3.00$22.60 67.0%111.19%CMPSCompass Pathways$11.813.6548 of 5 stars2.93$20.58 74.3%141.17%TYRATyra Biosciences$32.473.3144 of 5 stars2.85$46.50 43.2%131.16%NTLAIntellia Therapeutics$12.602.778 of 5 stars2.35$20.25 60.7%231.14%NGNENeurogene$27.712.9965 of 5 stars2.86$74.17 167.7%7Gap Down1.13%ALLOAllogene Therapeutics$2.002.5214 of 5 stars2.69$8.52 326.1%13Gap Down1.10%QUREuniQure$24.193.4453 of 5 stars2.53$42.83 77.1%17Gap Up1.09%CNTACentessa Pharmaceuticals$39.751.5209 of 5 stars2.21$40.70 2.4%141.09%INBXInhibrx Biosciences$101.322.3463 of 5 stars2.33$150.00 48.0%6Analyst DowngradeGap Up This page (NYSEARCA:BBC) was last updated on 5/26/2026 by MarketBeat.com Staff. From Our PartnersHey, it's Jon Najarian. The SpaceX IPO is right around the corner. But I discovered Elon may have something BIGGER planned. Check this out before June 9th...After being invited to the SpaceX launch headquarters in Cape Canaveral from one of Elon's top lobbyists… Hall...Banyan Hill Publishing | SponsoredThe SpaceX supplier that shipped 5 billion chips to StarlinkWhen Nvidia surged 770%, its data center cooling supplier Vertiv climbed 1,700%. When Apple ran 2,000%, suppli...Weiss Ratings | SponsoredThe S-1 just dropped. 22 days left.The SpaceX S-1 is now public - $18.7 billion in revenue, a $75 billion raise, and a June 12 Nasdaq listing con...Behind the Markets | SponsoredMy crisis of conscienceEmmet Savage - named in Irish America's Wall Street 50 as one of the most successful investors in the world - ...Porter & Company | SponsoredBetter than SpaceX? Grab this ticker instead.Larry Benedict generated $274 million for his clients by finding the trades most investors missed. Now he says...Brownstone Research | SponsoredYour book attachedBill Poulos is offering his 'Simple Options Trading For Beginners' guide at no cost - normally priced at $29.9...Profits Run | SponsoredTrump Admin to Pump $1 Billion into this “Off-the-Radar” AI StockThe U.S. government pumped more than $1 billion into Intel. The stock popped 128%. It pumped $400 million into...InvestorPlace | SponsoredOpportunity Forming in a U.S. Supply-Chain Weak Spot?America has a supply-chain problem with graphite - demand is climbing while dependence on foreign sources rema...i2i Marketing Group, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
